Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Functional Impact of Acute Respiratory Viral Infections in Older Adults

NCT07388173 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2026-01-15
Last updated
2026-05-08

Condition(s) studied

Respiratory Infections in Old Age

Study summary

The prevention of infectious diseases in older adults remains a major public health challenge, as acute respiratory infections are a leading cause of hospitalisation, mortality, and functional decline worldwide. Immunosenescence and environmental exposures increase susceptibility to infection and reduce vaccine effectiveness in this population. Respiratory viruses, including influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus, account for a substantial share of this burden, much of which is vaccine-preventable. However, their impact on functional decline and recovery in older adults remains insufficiently characterized. This international study aims to assess the effect of hospitalization for major respiratory viral infections on loss of autonomy in individuals aged 60 years and older, to inform targeted prevention and vaccination strategies.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female subjects aged 60 years or older * Hospitalized in a study center (emergency department, infectious disease, internal medicine or geriatric hospital wards…) for acute respiratory infection (refer to table 1 below for definition). * Confirmed positive PCR test for influenza, SARS-CoV-2, RSV, or human metapneumovirus (hMPV). Participants with co-infections with other viral or bacterial agents can be included. Exclusion Criteria: * Participants with conditions significantly impacting short-term functional status, such as severe disability (ADL score ≤2 or Clinical Frailty Scale ≥7), terminal illness, palliative care needs, or inability to comprehend and complete study questionnaires due to severe stroke sequelae, complete sensory loss, advanced dementia, or similar impairments. * Participants that refuse or are unable to answer the 3- and 6-months follow-up phone call assessments * Positive laboratory test for single (mono-infection) virus other than influenza, SARS-CoV-2, RSV, or human metapneumovirus (HMPV) * Participant in exclusion period for another study using an investigational / unapproved medicinal product. * Participant referred to in articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons : pregnant woman, parturient, breastfeeding mother, person deprived of liberty by judicial or administrative decision, persons undergoing psychiatric care under articles L.3212-1 and L.3213-1 who do not fall under article L.1121-8, persons admitted to a healthcare or social institution for purposes other than research, minors, person under legal protection or unable to express consent). * Individuals opposed to participating in the research * Staff members with a hierarchical relationship to the principal investigator

Primary outcome measure(s)

  • Evolution of Functional Dependency assessed by Activities of Daily Living (ADL) Score — Baseline, at hospital discharge, 3 months after discharge, and 6 months after discharge.
    Change in functional performance measured using the Activities of Daily Living (ADL) scale. The ADL score ranges from 0 to 6, where higher scores indicate better functional independence The ADL score ranges from 0 to 6, where higher scores indicate better functional independence.
  • Evolution of Functional Dependency assessed by Instrumental Activities of Daily Living (IADL) Score — Baseline, Day 7, 3 months after discharge, and 6 months after discharge.
    Change in functional performance measured using the Instrumental Activities of Daily Living (IADL) scale. The IADL score ranges from 0 to 8, where higher scores indicate better functional independence.

Trial sites (24)

FacilityCityRegionStatus
University of Rochester School of Medicine, Infectious Diseases Unit Rochester New York Recruiting
University Hospital of Amiens Amiens France Active Not Recruiting
Melun Hospital Melun France Recruiting
Villeneuve Saint Georges Hospital Paris France Active Not Recruiting
University Hospital of Poitiers Poitiers France Active Not Recruiting
University Hospital of Reims Reims France Active Not Recruiting
University Hospital of Tours Tours France Active Not Recruiting
Klinikum Bayreuth, Klinik für Geriatrie Bayreuth Germany Not Yet Recruiting
Abteilung Geriatrie Universitätsmedizin Göttingen, Abteilung Geriatrie Göttingen Germany Not Yet Recruiting
Uniklinikum Jena, Klinik für Geriatrie Jena Germany Not Yet Recruiting
Universitätsmedizin Mannheim, IV. Medizinische Klinik (Geriatrie) Mannheim Germany Not Yet Recruiting
Klinikum Ulm, Geriatrisches Zentrum Agaplesion Bethesda Ulm Germany Not Yet Recruiting
University of Bari, Bari Bari Italy Not Yet Recruiting
Azienda Ospedaliero Universitaria "Renato Dulbecco", Catanzaro Catanzaro Italy Not Yet Recruiting
ULSS 5 Polesana, Rovigo Rovigo Italy Not Yet Recruiting
ASL 1 Imperiese, Sanremo Sanremo Italy Not Yet Recruiting
Città di Torino, Torino Torino Italy Not Yet Recruiting
APSS Trento, Geriatria, Trento Trento Italy Not Yet Recruiting
ASUGI, Trieste Trieste Italy Not Yet Recruiting
ULSS 3 Serenissima, Venice Venice Italy Not Yet Recruiting
ULSS 9 Scaligera, Legnago, Verona Verona Italy Not Yet Recruiting
Hospital Clínic Barcelona Servicio de Geriatría Barcelona Spain Recruiting
Hospital Universitario Ramón y Cajal. Madrid Servicio de Geriatría Madrid Spain Not Yet Recruiting
Hospital Universitario Virgen de la Arrixaca Murcia Servicio de Geriatría Murcia Spain Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07388173 on ClinicalTrials.gov ↗ ← All trials in Spain